Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
art26 save search
Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy
Published: 2024-01-23 (Crawled : 13:30) - globenewswire.com
ARTL | $1.28 -1.94% 5.5K
|
Health Technology
|
| O: 0.0%
H: 3.6%
C: -0.72%
art26 pre-clinical publication research
Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12
Published: 2024-01-08 (Crawled : 14:00) - globenewswire.com
ARTL | $1.28 -1.94% 5.5K
|
Health Technology
|
| O: 3.09%
H: 0.0%
C: -3.65%
art26 worldwide trials research study
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers
Published: 2023-11-09 (Crawled : 14:00) - globenewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 2.33%
H: 0.83%
C: -0.88%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 2.72%
H: 0.49%
C: -1.79%
ARTL | $1.28 -1.94% 5.5K
|
Health Technology
|
| O: 3.47%
H: 0.0%
C: -11.41%
art27 art27.13 publication research
Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023
Published: 2023-11-02 (Crawled : 12:00) - globenewswire.com
ARTL | $1.28 -1.94% 5.5K
|
Health Technology
|
| O: 1.64%
H: 1.6%
C: 0.8%
art26 depression research preclinical
Artelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12Announces Plans to File IND Application in Neuropathic Pain
Published: 2023-09-07 (Crawled : 17:00) - biospace.com/
ARTL | $1.28 -1.94% 5.5K
|
Health Technology
|
| O: 3.83%
H: 22.13%
C: -25.45%
art26 fda positive meeting application
Artelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12
Published: 2023-09-07 (Crawled : 12:00) - globenewswire.com
ARTL | $1.28 -1.94% 5.5K
|
Health Technology
|
| O: 3.83%
H: 22.13%
C: -25.45%
art26 fda positive meeting
Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023
Published: 2023-07-19 (Crawled : 13:00) - globenewswire.com
ARTL | $1.28 -1.94% 5.5K
|
Health Technology
|
| O: 4.74%
H: 0.0%
C: -3.52%
art26 conference research
Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium
Published: 2023-06-27 (Crawled : 12:00) - globenewswire.com
ARTL | $1.28 -1.94% 5.5K
|
Health Technology
|
| O: 1.83%
H: 7.04%
C: -3.52%
art26 symposium positive international research
Artelo Biosciences Initiates the Phase 2a Portion of its CAReS Trial EvaluatingART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
Published: 2023-04-25 (Crawled : 13:00) - biospace.com/
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -2.02%
H: 0.67%
C: 0.67%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.91%
H: 0.08%
C: -1.1%
ARTL | $1.28 -1.94% 5.5K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -21.75%
art27 treatment cares trial
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight LossExpects to Commence Phase 2a of CAReS During the First Quarter of 2023
Published: 2023-02-02 (Crawled : 15:20) - biospace.com/
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -2.3%
H: 2.11%
C: 1.78%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.31%
H: 0.05%
C: -0.33%
ARTL | $1.28 -1.94% 5.5K
|
Health Technology
|
| O: -1.27%
H: 1.67%
C: -0.96%
art27 treatment cares trial art27.13 phase 2b
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
Published: 2023-02-02 (Crawled : 14:20) - globenewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -2.3%
H: 2.11%
C: 1.78%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.31%
H: 0.05%
C: -0.33%
ARTL | $1.28 -1.94% 5.5K
|
Health Technology
|
| O: -1.27%
H: 1.67%
C: -0.96%
art27 treatment cares trial art27.13 phase 2b
Artelo Biosciences Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
Published: 2022-07-19 (Crawled : 13:20) - globenewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -0.67%
H: 1.97%
C: 1.17%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 2.23%
H: 0.8%
C: 0.46%
ARTL | $1.28 -1.94% 5.5K
|
Health Technology
|
| O: 0.0%
H: 6.99%
C: 1.61%
art27 treatment art27.13 study
Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain
Published: 2022-06-27 (Crawled : 13:20) - biospace.com/
ARTL | $1.28 -1.94% 5.5K
|
Health Technology
|
| O: 1.07%
H: 9.17%
C: -1.64%
art26 pre-clinical positive results preclinical
Artelo Expands Collaboration with Trinity College Dublin to Investigate Cellular Biology of Fatty Acid Binding Protein (FABP) Inhibition In CancerNew Potential Uses of ART26.12 for Treating Tumors
Published: 2022-03-28 (Crawled : 17:00) - biospace.com/
ARTL | $1.28 -1.94% 5.5K
|
Health Technology
|
| O: -3.24%
H: 3.26%
C: -4.24%
art26 potential collaboration
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.